News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
ASCO Urges Lawmakers to Protect Federal Funding for Cancer Research and Prevention
May 4, 2025, 11:03

ASCO Urges Lawmakers to Protect Federal Funding for Cancer Research and Prevention

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

“ASCO is calling on lawmakers to uphold the U.S.’s role as a global leader in scientific and medical innovation and preserve vital federal cancer prevention and research funding.”

Read ASCO‘s statement.

ASCO

ASCO cancer Cancer research OncoDaily Oncology
Special Coverage
Opinion
May 4, 2025, 11:29
STELLAR II trial: Immunotherapy Combined with Radiotherapy and Chemotherapy Reduces the Need for Surgery in Locally Advanced Rectal Cancer
Blog
May 4, 2025, 11:26
Collaboration between National Societies and Patients can Strengthen Advocacy - ESTRO
Blog
May 4, 2025, 11:14
Marie-Catherine Vozenin Honored with Claudius Regaud Award at ESTRO 2025
Blog
May 4, 2025, 11:13
Princess Dina Mired: A true trailblazer in Pediatric Oncology by Carlos Rodriguez-Galindo
Blog
May 4, 2025, 11:11
Ina Jürgenliemk-Schulz Receives Iridium 192 Award at ESTRO 2025
Societies
May 4, 2025, 11:03
ASCO Urges Lawmakers to Protect Federal Funding for Cancer Research and Prevention
Blog
May 4, 2025, 10:59
Sarah Barrett: A great and busy start to ESTRO25
Blog
May 4, 2025, 10:57
Joanna Metzner-Sadurski: Proud of Ruiling Yuan for Moderating 2025 COP Webinar on Oncology Advocacy
Blog
May 4, 2025, 10:46
Theresa O Donovan: RTTs Experiences and Perceptions of Providing Support to Patients with Acute Psychosocial Distress
Blog
May 4, 2025, 10:39
Andrew Loblaw: 20 year Data Propensity-based analysis of LDR vs HDR boost
Blog
May 4, 2025, 10:29
Enar Recalde: Radiotherapy for Merkel cell carcinoma at ESTRO2025
Blog
May 4, 2025, 10:21
Piet Ost: Can Durvalumab and SBRT improve outcomes in Oligorecurrent Prostate Cancer?